Siqi Liao
机构：Dalian Medical University, Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University
发表论文 9 篇 · 总被引 49 次 · h-index 4
代表论文
- The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets (2025 · MedComm · 被引 19)
- The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway (2024 · Biogerontology · 被引 17)
- Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma (2024 · Journal of Translational Medicine · 被引 6)
- Research on Marketing Strategy of New energy Vehicles in China (2022 · Advances in economics, business and management research/Advances in Economics, Business and Management Research · 被引 6)
- FRI-500-YI ERAL1 down-regulates NADH: ubiquinone oxidoreductase core subunit V1 through N6-methyladenosine reader Insulin like growth factor 2 mRNA binding protein 2 to inhibit mitochondrial adenosine triphosphate synthesis and metastasis in hepatoma cells (2024 · Journal of Hepatology)
- 855 ERAL1 DOWNREGULATES NDUFV1 THROUGH M6A READER IGF2BP2 TO INHIBIT MITOCHONDRIAL ATP SYNTHESIS AND METASTASIS IN HEPATOMA CELLS (2024 · Gastroenterology)